Predict your next investment

Lief Therapeutics company logo
HEALTHCARE | Medical Devices & Equipment / Patient Monitoring
getlief.com

See what CB Insights has to offer

Founded Year

2011

Stage

Incubator/Accelerator - III | Alive

Total Raised

$250K

About Lief Therapeutics

Lief Therapeutics offers an ultra-thin wearable patch that measures users' heart and breath. Lief teaches users to control their body's natural stress response through gentle, safe biofeedback exercises.

Lief Therapeutics Headquarter Location

2443 Fillmore St #380-6060

San Francisco, California, 94115,

United States

Latest Lief Therapeutics News

Global Depression Treatment Market (2020 To 2026) - Featuring Allergen, Bausch Health Companies And Lief Therapeutics Among Others

Aug 5, 2021

Global Depression Treatment Market (2020 To 2026) - Featuring Allergen, Bausch Health Companies And Lief Therapeutics Among Others DUBLIN, Aug. 5, 2021 /PRNewswire/ -- The "Global Depression Treatment Market 2020-2026" report has been added to ResearchAndMarkets. Author: Aug 5, 2021 11:45 AM EDT DUBLIN, Aug. 5, 2021 /PRNewswire/ -- The "Global Depression Treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The rising prevalence of depression among the global population is the major factor driving the growth of the depression treatment market. Besides, the increasing awareness about mental illness, and the growing geriatric population with a higher rate of depression, is another factor accelerating the market growth. According to the report of the World Health Organization (WHO) published in January 2020, there are around 800,000 suicide-related mortalities every year, and 264 million people of all ages suffer from depression globally. Moreover, depression is the second leading cause of suicide in the young generation which is expected to increase due to change in lifestyle and increasing workload. The presence of depression disorder cases is higher in the US. According to the estimates of Anxiety and Depression Foundation facts and statistics, 6.8 million adults, or 3.1% of the US population have been affected by a generalized anxiety disorder. In line with this, 6 million adults, or 2.7% of the US population are affected by panic disorder. Other factors such as chronic medical conditions, crimes such as sexual abuse, femicide along other behavioral issues may further lead to depression, which in turn, creates demand for depression treatment drugs. Segmental OutlookThe global depression treatment market is segmented on the basis of drug type into selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and others. Selective Serotonin Reuptake Inhibitors (SSRIs) in Drug Type Segment Hold Significant Share The Selective Serotonin reuptake inhibitors (SSRI) segment is anticipated to grow at a significant pace during the forecast period. The SSRI is a type of drug used to treat mental illnesses such as depression and anxiety disorder by elevating the extracellular levels of serotonin. Selective serotonin reuptake inhibitors are widely used across the globe as they are highly effective in the treatment of depression. These are the most commonly prescribed antidepressant drugs, as it possesses maximum benefits with fewer side effects as compared to other drugs. Similar to other antidepressants, certain SSRIs are prescribed as a treatment for chronic pain conditions. Regional OutlookThe global depression treatment market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to be the leading region in the global depression treatment market and is expected to remain dominant during the forecast period. The factors contributing to the growth of this region include the presence of a large number of depression cases and the accessibility of antidepressants across the region. In addition, the government policies regarding drug launches and generic drug production are the major factors driving the growth of the depression treatment market.The Asia-Pacific is estimated to be the fastest-growing region in the depression treatment market during the forecast period (2021-2027). Global Depression Treatment Market Growth, by Region 2021-2027 Asia-Pacific is projected to have considerable growth in the global depression treatment market. Asia-Pacific is projected to be the fastest-growing market during the forecast period. The factor contributing to the growth of the depression treatment market in this region includes the rising prevalence of psychiatric disorders. Besides, the development of new therapies and devices to reduce the depression rate by investing high amounts through key market players are the key factors for the market growth. Moreover, the production of new antidepressant drugs in emerging countries such as China, India, Japan, and others is anticipated to drive the depression treatment market in the region. Market Players Outlook Some of the key players of the depression market include Eli Lilly and Co., Johnson & Johnson, Pfizer, Inc., Merck & Co., Inc., H. Lundbeck A/S., F. Hoffmann-La Roche Ltd, and others. In order to gain a strong position in the market, these players adopt various marketing strategies such as mergers & acquisitions, R&D, product launch, and geographical expansion so on. For instance, in August 2019, Lupin, a pharmaceutical company had launched an antidepressant drug Fluoxetine Tablets USP, 10 mg and 20 mg. The company had received the US FDA approval for Prozac which is indicated for the treatment of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder. The Report Covers Market value data analysis of 2019 and forecast to 2027. Annualized market revenues ($ million) for each market segment. Country-wise analysis of major geographical regions. Key companies operating in the global depression treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report. Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where in the market. Key Topics Covered: 1. Report Summary 2. Market Overview and Insights 3. Competitive Landscape3.1. Key Company Analysis3.1.1. Overview3.1.2. Financial Analysis3.1.3. SWOT Analysis3.1.4. Recent Developments3.2. Key Strategy Analysis 4. Market Determinants4.1. Motivators4.2. Restraints4.3. Opportunities 5. Market Segmentation5.1. Global Depression Treatment Market by Drugs Type5.1.1. Selective Serotonin Reuptake Inhibitors5.1.2. Tricyclic Antidepressants5.1.3. Serotonin-Norepinephrine Reuptake Inhibitors5.1.4. Monoamine Oxidase Inhibitors5.1.5. Others 6. Regional Analysis6.1. North America6.1.1. United States6.1.2. Canada6.2. Europe6.2.1. UK6.2.2. Germany6.2.3. Italy6.2.4. Spain6.2.5. France6.2.6. Rest of Europe6.3. Asia-Pacific6.3.1. China6.3.2. India6.3.3. Japan6.3.4. Rest of Asia-Pacific6.4. Rest of the World 7. Company Profiles7.1. Alkermes Plc7.2. Allergen Plc7.3. AstraZeneca plc7.4. Bausch Health Companies, Inc.7.5. Eli Lilly and Co.7.6. F. Hoffmann-La Roche AG7.7. Garmin Ltd.7.8. GlaxoSmithKline plc7.9. H. Lundbeck A/S7.10. Johnson & Johnson Services, Inc.7.11. Lief Therapeutics7.12. Lupin Ltd.7.13. MagVenture, Inc.7.14. Mylan N.V.7.15. Novartis AG7.16. Otsuka Pharmaceutical Co., Ltd.7.17. Pfizer, Inc.7.18. Sanofi SA7.19. Takeda Pharmaceutical Co. Ltd.7.20. Teva Pharmaceutical Industries Ltd. For more information about this report visit https://www.researchandmarkets.com/r/3a5vd Media Contact: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com    For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 View original content: https://www.prnewswire.com/news-releases/global-depression-treatment-market-2020-to-2026---featuring-allergen-bausch-health-companies-and-lief-therapeutics-among-others-301349333.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Lief Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Lief Therapeutics in 2 CB Insights research briefs, most recently on May 24, 2021.

Expert Collections containing Lief Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lief Therapeutics is included in 6 Expert Collections, including Digital Health.

D

Digital Health

11,684 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health/Wellness Tech

963 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

B

Beauty & Personal Care

857 items

These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

T

Telehealth

2,708 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

H

Health Monitoring & Diagnostics

1,300 items

Companies developing wearable health monitoring solutions (human health only). Companies tagged as #Wearables (*note: this tag may also apply to companies outside the scope of this collection)

Lief Therapeutics Patents

Lief Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Body shape
  • Brassieres
  • Lingerie
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/22/2018

Brassieres, Body shape, Lingerie, Progress (spacecraft) missions, Undergarments

Application

Application Date

2/22/2018

Grant Date

Title

Related Topics

Brassieres, Body shape, Lingerie, Progress (spacecraft) missions, Undergarments

Status

Application

Lief Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lief Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.